EPICC peptide platform with 160+ engineered peptides; lead pegtarazimod targets C1 + neutrophils; Phase 2 trials STAR (HIE), AURORA (GvHD), AE-COPD; $150M+ since 2018
No detailed funding rounds available.
Total known funding: